DK2401269T3 - Indolderivater som crth2-receptorantagonister - Google Patents

Indolderivater som crth2-receptorantagonister

Info

Publication number
DK2401269T3
DK2401269T3 DK10705068.4T DK10705068T DK2401269T3 DK 2401269 T3 DK2401269 T3 DK 2401269T3 DK 10705068 T DK10705068 T DK 10705068T DK 2401269 T3 DK2401269 T3 DK 2401269T3
Authority
DK
Denmark
Prior art keywords
incidental
derivatives
receptor antagonists
crth2 receptor
crth2
Prior art date
Application number
DK10705068.4T
Other languages
English (en)
Inventor
Carl Berthelette
Michael Boyd
John Colucci
Karine Villeneuve
Joey Methot
Original Assignee
Merck Sharp & Dohme
Merck Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme, Merck Canada Inc filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of DK2401269T3 publication Critical patent/DK2401269T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK10705068.4T 2009-02-24 2010-02-19 Indolderivater som crth2-receptorantagonister DK2401269T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15496809P 2009-02-24 2009-02-24
PCT/US2010/024713 WO2010099039A1 (en) 2009-02-24 2010-02-19 Indole derivatives as crth2 receptor antagonists

Publications (1)

Publication Number Publication Date
DK2401269T3 true DK2401269T3 (da) 2014-04-28

Family

ID=42046150

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10705068.4T DK2401269T3 (da) 2009-02-24 2010-02-19 Indolderivater som crth2-receptorantagonister

Country Status (36)

Country Link
US (2) US8394819B2 (da)
EP (2) EP2492267B1 (da)
JP (1) JP4989786B1 (da)
KR (2) KR101276530B1 (da)
CN (1) CN102333771B (da)
AR (1) AR075597A1 (da)
AU (1) AU2010218209B2 (da)
BR (1) BRPI1008906B1 (da)
CA (1) CA2752981C (da)
CL (1) CL2011002056A1 (da)
CO (1) CO6410295A2 (da)
CR (1) CR20110455A (da)
DK (1) DK2401269T3 (da)
DO (1) DOP2011000271A (da)
EA (1) EA021076B1 (da)
EC (1) ECSP11011288A (da)
ES (2) ES2529420T3 (da)
HN (1) HN2011002272A (da)
HR (1) HRP20140384T1 (da)
IL (1) IL214342A0 (da)
MA (1) MA33134B1 (da)
MX (1) MX2011008869A (da)
MY (1) MY152062A (da)
NI (1) NI201100162A (da)
NZ (1) NZ594767A (da)
PE (1) PE20120056A1 (da)
PL (1) PL2401269T3 (da)
PT (1) PT2401269E (da)
RS (1) RS53268B (da)
SG (1) SG173775A1 (da)
SI (1) SI2401269T1 (da)
TN (1) TN2011000382A1 (da)
TW (2) TWI454474B (da)
UA (1) UA105039C2 (da)
WO (1) WO2010099039A1 (da)
ZA (1) ZA201105767B (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8637671B2 (en) * 2008-09-22 2014-01-28 Merck Canada Inc. Indole derivatives as CRTH2 receptor antagonists
AU2009295231A1 (en) * 2008-09-22 2010-03-25 Merck Canada Inc. Azaindole derivatives as CRTH2 receptor antagonists
EP2661265B1 (en) 2010-12-23 2017-03-08 Merck Sharp & Dohme Corp. Quinolines and aza-quinolines as crth2 receptor modulators
ES2635030T3 (es) 2010-12-23 2017-10-02 Merck Sharp & Dohme Corp. Quinoxalinas y aza-quinoxalinas como moduladores del receptor CRTH2
JP5964945B2 (ja) * 2011-04-14 2016-08-03 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ ７−（ヘテロアリ−ル−アミノ）−６，７，８，９−テトラヒドロピリド［１，２−ａ］インド−ル酢酸誘導体及びプロスタグランジンＤ２受容体調節剤としてのそれらの使用
JP5629403B2 (ja) 2011-06-17 2014-11-19 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｃｒｔｈ２受容体モジュレータとしてのシクロアルキル縮合テトラヒドロキノリン
US20130072470A1 (en) 2011-09-21 2013-03-21 Abbvie Inc. Novel tricyclic compounds
CN103450218B (zh) * 2012-05-29 2015-12-23 山东亨利医药科技有限责任公司 作为crth2受体拮抗剂的吲哚类三并环衍生物
EP2922539B1 (en) 2012-10-01 2020-01-15 Merck Sharp & Dohme Corp. Substituted isoquinolines as crth2 receptor modulators
WO2014060596A1 (en) * 2012-10-18 2014-04-24 Zach System S.P.A. Process for preparing indole derivatives
CA2939892C (en) 2014-03-17 2020-03-31 Idorsia Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
CN106103437A (zh) 2014-03-18 2016-11-09 埃科特莱茵药品有限公司 氮杂吲哚乙酸衍生物及其作为前列腺素d2受体调节剂的用途
JP6938383B2 (ja) 2015-04-02 2021-09-22 インターベット インターナショナル ベー． フェー． イヌインターロイキン４受容体アルファに対する抗体
WO2017005764A1 (en) * 2015-07-07 2017-01-12 Intervet International B.V. A process to make tricycloketone intermediates of crth2 antagonists
WO2017005759A1 (en) 2015-07-07 2017-01-12 Intervet International B.V. A process to make azaindole derivatives
WO2017005766A1 (en) 2015-07-07 2017-01-12 Intervet International B.V. A process to make tricycic alcohol intermediates of crth2 antagonists
EP3337803B1 (en) * 2015-07-23 2022-08-17 Merck Sharp & Dohme LLC Genetic markers associated with response to crth2 receptor antagonists
CN108026093B (zh) 2015-09-15 2021-11-16 爱杜西亚药品有限公司 结晶形式
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
SG10201913999PA (en) 2015-10-16 2020-03-30 Abbvie Inc PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12071666B2 (en) 2016-12-14 2024-08-27 Merck Sharp & Dohme Llc Human genetic markers associated with response to treatments that target clostridium difficile toxin B
CN114829396A (zh) 2019-12-20 2022-07-29 英特维特国际股份有限公司 用于治疗特应性皮炎的双特异性犬源化抗体和双特异性结合伴体
US20240368249A1 (en) 2021-08-20 2024-11-07 Intervet Inc. Fusion proteins for treating atopic dermatitis

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
WO1995015973A1 (en) 1993-12-06 1995-06-15 Cytel Corporation Cs-1 peptidomimetics, compositions and methods of using the same
US5510332A (en) 1994-07-07 1996-04-23 Texas Biotechnology Corporation Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
WO1996001644A1 (en) 1994-07-11 1996-01-25 Athena Neurosciences, Inc. Inhibitors of leukocyte adhesion
US5811391A (en) 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
GB9524630D0 (en) 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
WO1996031206A2 (en) 1995-04-07 1996-10-10 Warner-Lambert Company Flavones and coumarins as agents for the treatment of atherosclerosis
WO1996040781A1 (en) 1995-06-07 1996-12-19 Tanabe Seiyaku Co., Ltd. CYCLIC PEPTIDE INHIBITORS OF β1 AND β2 INTEGRIN-MEDIATED ADHESION
EP0842195A1 (en) 1995-07-06 1998-05-20 Zeneca Limited Peptide inhibitors of fibronectine
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
FR2827206B1 (fr) 2001-07-10 2004-04-02 Nature Bois Emballages Procede et dispositif de formage de planchettes, et emballages comportant de telles planchettes
WO2003097598A1 (en) 2002-05-16 2003-11-27 Shionogi & Co., Ltd. Compound exhibiting pgd 2 receptor antagonism
EP1631547A1 (en) * 2003-05-20 2006-03-08 Merck Frosst Canada Ltd. Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin d2 antagonists
US7714132B2 (en) * 2004-03-11 2010-05-11 Actelion Pharmaceuticals, Ltd. Tetrahydropyridoindole derivatives
TW200605885A (en) 2004-07-29 2006-02-16 Threshold Pharmaceuticals Inc Multicyclic lonidamine analogs
GB0427381D0 (en) * 2004-12-14 2005-01-19 Novartis Ag Organic compounds
ES2369782T3 (es) * 2004-12-27 2011-12-05 Actelion Pharmaceuticals Ltd. Derivados de 2,3,4,9-tetrahidro-1h-carbazol como antagonistas del receptor crth2.
GB0505048D0 (en) * 2005-03-11 2005-04-20 Oxagen Ltd Compounds with PGD antagonist activity
AU2006281937B2 (en) 2005-08-12 2011-11-17 Merck Canada Inc. Indole derivatives as CRTH2 receptor antagonists
MY147588A (en) * 2006-08-07 2012-12-31 Actelion Pharmaceuticals Ltd (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives
US20110112134A1 (en) 2008-05-16 2011-05-12 Amira Pharmaceuticals, Inc. Tricyclic Antagonists of Prostaglandin D2 Receptors
AU2009295229B2 (en) 2008-09-22 2014-02-27 Merck Canada Inc. Indole derivatives as CRTH2 receptor antagonists
US8637671B2 (en) 2008-09-22 2014-01-28 Merck Canada Inc. Indole derivatives as CRTH2 receptor antagonists
AU2009295231A1 (en) 2008-09-22 2010-03-25 Merck Canada Inc. Azaindole derivatives as CRTH2 receptor antagonists
WO2010085820A2 (en) 2009-01-26 2010-07-29 Amira Pharmaceuticals, Inc. Tricyclic compounds as antagonists of prostaglandin d2 receptors

Also Published As

Publication number Publication date
EP2401269A1 (en) 2012-01-04
BRPI1008906B1 (pt) 2019-10-15
SG173775A1 (en) 2011-09-29
TN2011000382A1 (en) 2013-03-27
KR101276530B1 (ko) 2013-06-18
ES2450594T3 (es) 2014-03-25
NI201100162A (es) 2012-02-01
PL2401269T3 (pl) 2014-07-31
PT2401269E (pt) 2014-03-11
TWI454474B (zh) 2014-10-01
PE20120056A1 (es) 2012-02-05
HN2011002272A (es) 2014-02-24
ES2529420T3 (es) 2015-02-19
ECSP11011288A (es) 2011-10-31
TW201035096A (en) 2010-10-01
CN102333771B (zh) 2014-03-19
EP2401269B1 (en) 2014-01-29
BRPI1008906A2 (pt) 2016-03-15
CA2752981C (en) 2013-11-12
EP2492267A1 (en) 2012-08-29
HK1160465A1 (en) 2012-08-17
CL2011002056A1 (es) 2012-04-09
CO6410295A2 (es) 2012-03-30
MA33134B1 (fr) 2012-03-01
ZA201105767B (en) 2012-04-25
TW201402573A (zh) 2014-01-16
CR20110455A (es) 2012-01-10
US8394819B2 (en) 2013-03-12
NZ594767A (en) 2013-05-31
KR20130028156A (ko) 2013-03-18
SI2401269T1 (sl) 2014-04-30
US20100234415A1 (en) 2010-09-16
DOP2011000271A (es) 2011-10-15
KR101275980B1 (ko) 2013-06-17
CA2752981A1 (en) 2010-09-02
MY152062A (en) 2014-08-15
CN102333771A (zh) 2012-01-25
AU2010218209B2 (en) 2012-12-13
HRP20140384T1 (en) 2014-05-23
EA021076B1 (ru) 2015-03-31
IL214342A0 (en) 2011-09-27
EP2492267B1 (en) 2014-11-26
RS53268B (sr) 2014-08-29
UA105039C2 (uk) 2014-04-10
MX2011008869A (es) 2011-12-16
TWI444381B (zh) 2014-07-11
JP4989786B1 (ja) 2012-08-01
AR075597A1 (es) 2011-04-20
WO2010099039A1 (en) 2010-09-02
US20130150398A1 (en) 2013-06-13
JP2012517484A (ja) 2012-08-02
AU2010218209A1 (en) 2011-08-25
EA201171081A1 (ru) 2012-02-28
US9023864B2 (en) 2015-05-05
KR20110107395A (ko) 2011-09-30

Similar Documents

Publication Publication Date Title
HUS2200033I1 (hu) CGRP receptor antagonisták
LTPA2020528I1 (lt) Benzimidazolo dariniai
IL214342A0 (en) Indole derivatives as crth2 receptor antagonists
DK2501703T3 (da) Spiropiperidinforbindelser som orl-1-receptorantagonister
ECSP12011999A (es) Derivados benzamida sustituidos
DK2501704T3 (da) Spiropiperidinforbindelser som oral-1-receptorantagonister
DK2821407T3 (da) Piperidinoncarboxamidazaindan-cgrp receptorantagonister
DK2250161T3 (da) Forbindelser med CRTH2-antagonistaktivitet
DK2308877T3 (da) Imidazopyridin-2-on-derivater
DK2443104T3 (da) Disubstituerede phthalazin-hedgehog-sti-antagonister
DK2401270T3 (da) Pyrazolderivater anvendt som CCR4-receptorantagonister.
DK2397480T3 (da) Diazepindionderivat
DK2275414T3 (da) Cyclopentylacrylamidderivat
ATE545635T1 (de) Substituierte n-oxidpyrazinderivate
DK2387580T3 (da) Deoxyactagardinderivater
DK2205569T3 (da) Alkylthiopyrimidiner som crth2-antagonister
IL209733A0 (en) New benzimidazole derivatives
PL2452019T3 (pl) Konstrukcja kładki
BRPI1011416A2 (pt) derivados de antraquinova novos
SMT201300020B (it) Derivati di isochinolinone come antagonisti dei recettori nk3
ATE534634T1 (de) 2-phenyl-4-cyclopropyl-pyrimidinderivate
DK2148873T3 (da) 4-alkoxypyridazinderivater som hurtigt dissocierende dopamin 2- receptorantagonister
EP2460796A4 (en) indole derivative
BRPI0908008A2 (pt) Farmacóforo dual - pde4-antagonistas muscarínicos
EP2394990A4 (en) INDOLINE DERIVATIVES